These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 30683379)
1. Quantification of gemcitabine intravenous drugs by direct measurement in chemotherapy plastic bags using a handheld Raman spectrometer. Lê L; Berge M; Tfayli A; Baillet Guffroy A; Prognon P; Dowek A; Caudron E Talanta; 2019 May; 196():376-380. PubMed ID: 30683379 [No Abstract] [Full Text] [Related]
2. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. Lanz C; Früh M; Thormann W; Cerny T; Lauterburg BH J Sep Sci; 2007 Aug; 30(12):1811-20. PubMed ID: 17638352 [TBL] [Abstract][Full Text] [Related]
3. Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies. Chen G; Svirskis D; Wen J J Pharm Pharmacol; 2015 Nov; 67(11):1528-36. PubMed ID: 26369422 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. O'Rourke TJ; Brown TD; Havlin K; Kuhn JG; Craig JB; Burris HA; Satterlee WG; Tarassoff PG; Von Hoff DD Eur J Cancer; 1994; 30A(3):417-8. PubMed ID: 8204374 [No Abstract] [Full Text] [Related]
5. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. Freeman KB; Anliker S; Hamilton M; Osborne D; Dhahir PH; Nelson R; Allerheiligen SR J Chromatogr B Biomed Appl; 1995 Mar; 665(1):171-81. PubMed ID: 7795789 [TBL] [Abstract][Full Text] [Related]
7. Modified approach of administering cytostatics to the lung: more efficient isolated lung perfusion. van Putte BP; Hendriks JM; Guetens G; de Boeck G; de Bruijn EA; van Schil PE; Folkerts G Ann Thorac Surg; 2006 Sep; 82(3):1033-7. PubMed ID: 16928530 [TBL] [Abstract][Full Text] [Related]
8. Questions about gemcitabine dose rate: answered or unanswered? Gandhi V J Clin Oncol; 2007 Dec; 25(36):5691-4. PubMed ID: 18089862 [No Abstract] [Full Text] [Related]
13. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. Gontero P; Marini L; Frea B BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511 [No Abstract] [Full Text] [Related]
14. Gemcitabine and the interaction with anticoagulants. Kilgour-Christie J; Czarnecki A Lancet Oncol; 2002 Aug; 3(8):460. PubMed ID: 12147431 [No Abstract] [Full Text] [Related]
15. Use of gemcitabine (GEM) in advanced myelodysplastic syndromes. Mario AD; Pagano L; Mele L; De Stefano V; Leone G Ann Oncol; 2001 Oct; 12(10):1494. PubMed ID: 11762826 [No Abstract] [Full Text] [Related]
16. Gemcitabine doublets in advanced pancreatic cancer: should we move on? Rocha Lima CM; Flores AM J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312 [No Abstract] [Full Text] [Related]
17. Gemcitabine and platinum combinations in pancreatic cancer. Philip PA Cancer; 2002 Aug; 95(4 Suppl):908-11. PubMed ID: 12209670 [TBL] [Abstract][Full Text] [Related]